Serial life sciences entrepreneur Dr Stephen Little honoured at 16th Annual Bionow Awards
The outstanding contribution made to life sciences by entrepreneur Dr Stephen Little, Chief Executive of AIM-listed molecular diagnostics company Premaitha Health, was recognised last night at the 16th annual Bionow Awards.
Dr Little, who led Premaitha through its successful AIM listing in July 2014, has an impressive track record of building biotech businesses and creating value.
He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5m in 2001 and was sold to QIAGEN in 2009 for £85m. Before DxS, Dr Little worked for 20 years in various senior positions in the diagnostic divisions of AstraZeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh.
Premaitha operates from a base at Rutherford House on the MSP campus, Manchester Science Park, in central Manchester. The success of another MSP customer, ApconiX, which is located at Alderley Park, was also celebrated at the event, which gathers together the outstanding leaders and innovators in the life sciences sector in the North of England.
ApconiX was named Start Up of the Year. The company, founded in 2015, provides nonclinical safety consultancy, from project initiation through to worldwide marketing approval.
Dr Chris Doherty, managing director of Alderley Park, commented: “The standard of entries across all the categories at this year’s Bionow awards was deeply impressive and augurs well for the continued growth of the life science sector in the North. ApconiX has made very rapid progress and has an outstanding management team – we are all delighted to see the business receive this recognition.”
In the highly sought-after Company of the Year category, Keele Science Park-based Cobra Biologics was triumphant. Cobra, an international contract development and manufacturer of biologics and pharmaceuticals, is in the midst of a £15m expansion programme in the UK and Sweden. The company, which manufactures DNA and viral vectors for the gene therapy market, exports 98% of its products.
A £700,000 fundraising by University of Manchester spin-out company Microbiosensor, which develops disposable point-of-care medical devices, was named Investment Deal of the Year, while Peter Chater a research associate at the University of Newcastle won in the prestigious Promising Technologist of the Year category.
The awards, which recognise excellence, outstanding achievement and enterprise in a sector that is worth £11bn to the North’s economy, were sponsored by Manchester Science Partnerships, Appleyard Lees and World Courier.
The full list of winners was:
Bionow Start Up of the Year Award (Sponsored by RSM)
Bionow Healthcare Project of the Year Award (Sponsored by TRUSTECH)
Sky Medical Technology / James Cook University Hospital South Tees NHS Trust -
Reducing the time to surgery for ankle fracture patients.
Bionow Project of the Year Award (Sponsored by Waters Corporation)
University of Manchester, test for the management and assessment of Inflammatory Bowel Disease
Bionow Product of the Year Award (Sponsored by The Innovation Agency)
Crawford Healthcare – KerraContact Ag
Bionow Technical Service Award (Sponsored by Gateley plc)
Cobra Biologics - Delivery of Technical Services related to the process development and manufacture of Plasmid DNA for Gene Therapy Products in clinical trials
Bionow Business Services Award (Sponsored by World Courier)
Innovation Agency, Healthcare Business Connect
Bionow Promising Technologist of the Year Award (Sponsored by Seqirus)
Peter Chater, Postdoctoral Research Associate, Newcastle University
Bionow Investment Deal of the Year Award (Sponsored by QIAGEN)
Microbiosensor Limited - Series A investment in Microbiosensor by Catapult Ventures and Maven Capital Partners
Bionow Outstanding Contribution Award (Sponsored by Sci-Tech Daresbury)
Dr Steve Little, Chief Executive Officer, Premaitha Health plc
Bionow Company of the Year Award (Sponsored by AstraZeneca)
Dr Geoff Davison, chief executive of Bionow, said: “The critical importance of the life sciences sector has been acknowledged in the Government’s new Industrial Strategy this week. It is hugely pleasing to see new financial support and a clear focus on supporting R&D-focused businesses and encouraging collaboration with the NHS as part of this.
“Locally it’s great to see a leading international company like QIAGEN announcing plans to grow its presence in the North – a clear vote of confidence in our sector.”
Dr Davison added: “As ever we had an incredibly strong shortlist all are to be commended for their innovation in providing solutions which have the potential to be game-changing in the industry.
“Steve Little is unquestionably one of the most successful entrepreneurs in our sector and he thoroughly deserves recognition for what he has achieved.”
A not-for-profit membership organisation, Bionow supports the North of England’s burgeoning life sciences sector, which currently includes some 1,000 science and healthcare companies with a combined turnover of around £10.9bn. Its member base includes start-ups and spin-outs as well as well-established businesses. The services it offers to firms include dedicated business support programmes, shared procurement schemes and recruitment and training support.